CTRI/2010/091/002961已完成2 期
A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to Anastrozole alone, in Post-menopausal Women With Hormone Receptor-positive, Endocrine Therapy-naïve, Locally-advanced or Metastatic Breast Cancer. - MINT
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients that have locally advanced or metastatic breast cancer. Lesions should not be amenable to surgery or radiation of curative intent
- •- Hormone therapy-naive
- •- Estimated life expectancy of more than 12 weeks
排除标准
- •- Last dose of prior anti-cancer therapy received within 14 days (or longer if required)
- •- Any eye injury or corneal surgery within 3 months prior to receiving first dose of study drug.
- •- Currently receiving (and unwilling to discontinue) oestrogen replacement therapy. (last dose <7 days prior to randomisation)
研究者
相似试验
进行中（未招募）
1 期
A study of AZD8931 and anastrozole for hormone receptor positive advanced breast cancer (MINT)ocally Advanced or Metastatic Breast CancerMedDRA version: 13.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012934-63-GBAstraZeneca AB345
进行中（未招募）
不适用
A study of AZD8931 and anastrozole for hormone receptor positive advanced breast cancer (MINT)ocally Advanced or Metastatic Breast CancerMedDRA version: 14.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012934-63-FIAstraZeneca AB345
进行中（未招募）
不适用
A study of AZD8931 and anastrozole for hormone receptor positive advanced breast cancer (MINT)EUCTR2009-012934-63-CZAstraZeneca AB345
已完成
2 期
A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centered Safety, Tolerability and Efficacy Study of RSD1235-SR to Prevent Atrial Fibrillation (AF) Recurrence in Subjects Post-Conversioarrythmiapalpitations10007521NL-OMON30473Cardiome Pharma60
进行中（未招募）
1 期
Study to Assess the Efficacy and Safety of MEDI3506 in Adults with Uncontrolled Moderate-to-severe Asthmancontrolled moderate-to-severe asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-000789-40-DEAstraZeneca AB228